161 related articles for article (PubMed ID: 14563637)
1. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.
Farag SS; Flinn IW; Modali R; Lehman TA; Young D; Byrd JC
Blood; 2004 Feb; 103(4):1472-4. PubMed ID: 14563637
[TBL] [Abstract][Full Text] [Related]
2. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
Hatjiharissi E; Hansen M; Santos DD; Xu L; Leleu X; Dimmock EW; Ho AW; Hunter ZR; Branagan AR; Patterson CJ; Kortsaris A; Verselis S; Fox E; Treon SP
Clin Lymphoma Myeloma; 2007 Jan; 7(4):286-90. PubMed ID: 17324336
[TBL] [Abstract][Full Text] [Related]
3. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Weng WK; Levy R
J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
6. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
Lin TS; Flinn IW; Modali R; Lehman TA; Webb J; Waymer S; Moran ME; Lucas MS; Farag SS; Byrd JC
Blood; 2005 Jan; 105(1):289-91. PubMed ID: 15217834
[TBL] [Abstract][Full Text] [Related]
7. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
8. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
Byrd JC; Murphy T; Howard RS; Lucas MS; Goodrich A; Park K; Pearson M; Waselenko JK; Ling G; Grever MR; Grillo-Lopez AJ; Rosenberg J; Kunkel L; Flinn IW
J Clin Oncol; 2001 Apr; 19(8):2153-64. PubMed ID: 11304767
[TBL] [Abstract][Full Text] [Related]
9. Effect of FCGR2A and FCGR3A variants on CLL outcome.
Dornan D; Spleiss O; Yeh RF; Duchateau-Nguyen G; Dufour A; Zhi J; Robak T; Moiseev SI; Dmoszynska A; Solal-Celigny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Rossiev VA; Bence-Bruckler I; Geisler CH; Montillo M; Wenger MK; Weisser M
Blood; 2010 Nov; 116(20):4212-22. PubMed ID: 20705761
[TBL] [Abstract][Full Text] [Related]
10. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
11. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype.
Congy-Jolivet N; Bolzec A; Ternant D; Ohresser M; Watier H; Thibault G
Cancer Res; 2008 Feb; 68(4):976-80. PubMed ID: 18281470
[TBL] [Abstract][Full Text] [Related]
12. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
13. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Fc gamma receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura.
Fujimoto TT; Inoue M; Shimomura T; Fujimura K
Br J Haematol; 2001 Oct; 115(1):125-30. PubMed ID: 11722422
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
16. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
17. Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Zhuang Y; Xu W; Shen Y; Li J
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):347-52. PubMed ID: 21030347
[TBL] [Abstract][Full Text] [Related]
18. Relevance of Fc gamma RIIIa-158V-F polymorphism to recurrence of adult periodontitis in Japanese patients.
Sugita N; Yamamoto K; Kobayashi T; Van Der Pol W; Horigome T; Yoshie H; Van De Winkel JG; Hara K
Clin Exp Immunol; 1999 Aug; 117(2):350-4. PubMed ID: 10444269
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
Weng WK; Negrin RS; Lavori P; Horning SJ
J Clin Oncol; 2010 Jan; 28(2):279-84. PubMed ID: 19933905
[TBL] [Abstract][Full Text] [Related]
20. Absence of association between the Fc gamma receptor IIIA-176F/V polymorphism and the severity of malaria in Thai.
Omi K; Ohashi J; Patarapotikul J; Hananantachai H; Naka I; Looareesuwan S; Tokunaga K
Jpn J Infect Dis; 2002 Oct; 55(5):167-9. PubMed ID: 12501257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
